0 442

Cited 12 times in

Hemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease

DC Field Value Language
dc.contributor.author강석구-
dc.contributor.author김세훈-
dc.date.accessioned2017-10-26T08:08:03Z-
dc.date.available2017-10-26T08:08:03Z-
dc.date.issued2016-
dc.identifier.issn1068-9265-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/153008-
dc.description.abstractBACKGROUND: Hemangiopericytoma (HPC) in the central nervous system (CNS) is a rare disease with distinctive biological/clinical characteristics compared with meningioma. METHODS: Cases of HPCs of the CNS were collected, and clinicopathological records were retrospectively reviewed and analyzed. Immunohistochemistry (IHC) for proliferative markers (Ki-67, PHH3) and STAT6 were performed. RESULTS: A total of 140 cases were collected, with mean follow-up of 77 months (median 58.8 months; range 0.53-540.5 months). 1-, 5-, 10-, and 20-year survival rates were 99.1, 94.0, 74.4, and 61.9 %, respectively. Thirty-nine patients (27.9 %) had recurrent disease. Mean and median times to recurrence were 62.9 and 47.3 months with 1-, 5-, 10-, and 20-year recurrence-free survival rates of 98.3, 78.3, 50.1, and 11.0 %, respectively. Thirteen patients (9.3 %) developed extracranial metastases. No adjuvant radiation therapy, higher histologic grades, failure of gross-total resection, and cases with gamma-knife surgery (GKS) were factors associated with shorter disease-free survival (log-rank test, p = 0.02, 0.00, 0.02, 0.00), among which high histologic grade and cases with GKS were significant in multivariable analysis. Strong nuclear STAT6 expression was noted in HPCs in 62 cases of HPCs (60/62, 96.8 %), whereas diffuse weak positivity was demonstrated in all meningioma cases. CONCLUSIONS: The survival rate in patients with HPC of the CNS is comparable to that of previously reported series. Recurrence remains a critical clinical issue of the disease. Identification of NAB2-STAT6 fusion transcript with surrogate IHC marker is a valuable diagnostic tool in the differential diagnosis of the disease.-
dc.description.statementOfResponsibilityrestriction-
dc.publisherSpringer-
dc.relation.isPartOfANNALS OF SURGICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleHemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Neurosurgery-
dc.contributor.googleauthorJunjeong Choi-
dc.contributor.googleauthorSung-Hye Park-
dc.contributor.googleauthorShin Kwang Khang-
dc.contributor.googleauthorYeon-Lim Suh-
dc.contributor.googleauthorSang Pyo Kim-
dc.contributor.googleauthorYoun Soo Lee-
dc.contributor.googleauthorHyun Seok Kwon-
dc.contributor.googleauthorSeok-Gu Kang-
dc.contributor.googleauthorSe Hoon Kim-
dc.identifier.doi10.1245/s10434-016-5414-x-
dc.contributor.localIdA00610-
dc.contributor.localIdA00036-
dc.relation.journalcodeJ00179-
dc.identifier.eissn1534-4681-
dc.identifier.pmid27444109-
dc.identifier.urlhttps://link.springer.com/article/10.1245%2Fs10434-016-5414-x-
dc.contributor.alternativeNameKang, Seok Gu-
dc.contributor.alternativeNameKim, Se Hoon-
dc.contributor.affiliatedAuthorKim, Se Hoon-
dc.contributor.affiliatedAuthorKang, Seok Gu-
dc.citation.volume23-
dc.citation.numberSuppl. 5-
dc.citation.startPage954-
dc.citation.endPage961-
dc.identifier.bibliographicCitationANNALS OF SURGICAL ONCOLOGY, Vol.23(Suppl. 5) : 954-961, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid41016-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.